Gemcitabine

• UNSPSC Description:

  Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[1][2].

• Target Antigen:

  Apoptosis; Autophagy; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Gemcitabine.html

• Solubility:

  DMSO : 200 mg/mL (ultrasonic)|Ethanol : 12.5 mg/mL (ultrasonic)|H2O : 6.25 mg/mL (ultrasonic;warming)

• Smiles:

  NC(C=CN1[C@H]2C(F)(F)[C@H](O)[C@@H](CO)O2)=NC1=O

• Molecular Weight:

  263.2

• References & Citations:

  [1]Wang H, et al. Enhanced efficacy of Gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrativenucleoside transporter 1. Anticancer Res. 2011 Oct;31(10):3171-80.|[2]Yip-Schneider MT, et al. Dimethylaminoparthenolide and Gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 17;13:194.|[3]Gagnadoux F, et al. Safety of pulmonary administration of gemcitabine in rats. J Aerosol Med. 2005 Summer;18(2):198-206|[4]Yusheng Cai, et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell Res. 2020 Jul;30(7):574-589.Acta Biochim Biophys Sin. 2021 Jan 12;gmaa177.|Acta Pharmacol Sin. 2023 Dec 6.|Adv Mater. 2021 May;33(18):e2100949.|Adv Sci (Weinh). 2023 Feb 19;e2206004.|Adv Sci (Weinh). 2023 Oct 22:e2302498.|Adv Sci (Weinh). 2023 Sep 3;e2303872.|Adv Sci (Weinh). 2024 Aug 23:e2400156.|Adv Ther. 2024 Jul 18.|Aging. 2020 Aug 28;12(16):16304-16325.|Am J Cancer Res. 2020 Nov 1;10(11):3896-3910.|Am J Cancer Res. 2020 Apr 1;10(4):1182-1193.|Arch Toxicol. 2023 Dec;97(12):3209-3226.|ÁREA DE FARMACIA Y TECNOLOGÍA FARMACÉUTICA. DEPARTAMENTO DE INGENIERÍA. 2020 Oct.|Biochem Pharmacol. 2020 Jun 6;114085. |Biochem Pharmacol. 2021 Oct 18;193:114813.|Biochem Pharmacol. 2024 Apr 24:116234.|Biol Pharm Bull. 2021 Dec 22.|Biomaterials. 16 September 2022.|Biomed Pharmacother. 2019 Sep;117:109185.|Biomed Pharmacother. 2022 Feb 11;148:112713.|Biomed Pharmacother. 2023 Aug 31;166:115389.|bioRxiv. 2023 Feb 28.|bioRxiv. 2023 Feb 7.|bioRxiv. 2023 Sep 5.|bioRxiv. 2024 Aug 6:2024.03.21.586169.|bioRxiv. 2024 June 12.|Breast Cancer Res Treat. 2023 May 19.|Cancer Lett. 2022 Jun 28;536:215651.|Cancer Lett. 2022 Nov 24;216023.|Cancer Lett. 2024 Oct 2:217284.|Cancer Med. 2019 Oct;8(13):5903-5915.|Cell Death Discov. 2021 May 1;7(1):89.|Cell Mol Life Sci. 2021 Oct 13.|Cell Mol Life Sci. 2024 Oct 5;81(1):417.|Cell Prolif. 2021 Apr 1;e13038.|Cell Rep Med. 2023 Jan 10;100911.|Cell Rep Med. 2023 Oct 17;4(10):101234.|Cell Rep. 2022 Aug 16;40(7):111194.|Cell Rep. 2024 Apr 23;43(4):114088.|Cell Res. 2020 Jul;30(7):574-589.|Chem Biol Interact. 2018 Jun 25;290:44-51.|Chem Eng J. 2023 Nov 17, 147466.|Chem Eng J. 2024 Sep 1.|Chinese Chemical Letters. |Chinese Pharmacological Bulletin. 2017, 33(6): 788-792.|Clin Transl Oncol. 2022 Jul 19.|DNA Cell Biol. 2021 Dec 13.|Elife. 2022 May 3;11:e69255.|Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):649-659. |Exp Cell Res. 2020 Dec 1;397(1):112335.|Front Oncol. 2021 Jul 13;11:704042.|Gastroenterology. 2021 Nov;161(5):1601-1614.e23.|Heliyon. 2024 June 28.|Hepatology. 2019 May;69(5):1995-2012. |Immun Inflamm Dis. 2023 Jun 14.|Inflamm Res. 2022 Oct 27.|Int Immunopharmacol. 2023 Jul 27;123:110709.|Int J Biol Sci. 2022 Jul 4;18(11):4301-4315.|Int J Biol Sci. 2022; 18(1):43-64.|Int J Clin Exp Pathol. 2017;10(3):3033-3042.|Int J Hyperthermia. 2024 Feb 12;41(1):2316085.|Int J Med Sci. 2022; 19(2): 286-298.|Invest New Drugs. 2022 Jan 4.|iScience. 6 September 2022, 105081.|J Biol Chem. 2017 Jun 2;292(22):9136-9149.|J Biol Chem. 2023 Jun 28;104984.|J Biomed Inform. 2023 May 15;104383.|J Cancer Res Clin Oncol. 2024 Jul 13;150(7):348.|J Cannabis Res. 2024 May 8;6(1):22.|J Clin Invest. 2024 Mar 7:e172716.|J Control Release. 2023 Aug 4;361:161-177.|J Ethnopharmacol. 2024 Mar 19:328:118075.|J Exp Clin Cancer Res. 2021 Nov 25;40(1):373.|J Exp Clin Cancer Res. 2022 Oct 5;41(1):293.|J Exp Clin Cancer Res. 2023 May 4;42(1):111.|J Immunother Cancer. 2024 Sep 4;12(9):e009318.|J Mater Chem B. 2023 Oct 11.|J Med Chem. 2024 Aug 20.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Nanobiotechnology. 2022 Jul 6;20(1):315.|J Pancreatol. 2023 Dec 12.|J Transl Med. 2023 Nov 21;21(1):838.|J Transl Med. 2024 Jan 13;22(1):55.|Mater Today Nano. 2024 Aug.|Mol Cancer. 2023 Dec 4;22(1):195.|Mol Cancer. 2024 Apr 29;23(1):86.|Mol Cancer. 2024 Jan 10;23(1):12.|Mol Cancer. 2024 Sep 30;23(1):215.|Mol Carcinog. 2024 Jan 30.|Mol Carcinog. 2024 Jul 17.|Mol Immunol. 2019 May;109:140-148. |Mol Pharm. 2021 Jun 2.|Molecules. 2022, 27(20), 6849.|Nat Commun. 2024 Oct 2;15(1):8540.|Nat Med. 2024 Mar;30(3):749-761.|Nature. 2019 Oct;574(7777):264-267. |Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):615-622.|Onco Targets Ther. 2020 Sep 28;13:9543-9558.|Oncogene. 2023 Aug 31.|Oncol Lett. June 30, 2021.|Oncol Rep. 2022 Feb;47(2):33.|Oncol Res. 2024 Nov 13;32(12):1867-1879.|Oxid Med Cell Longev. 2022 Sep 29;2022:3243647.|Patent. US20210260092A1.|Patent. US20220362387A1.|Patent. US20240344020A1.|Pharmacol Res. 2024 May 9:204:107208.|Phytomedicine. 2024 Apr 26:155656.|Phytomedicine. 2024 Mar 11, 155527.|Phytomedicine. 2024 Sep 7:135:156022.|Phytomedicine. 6 July 2022, 154323.|Phytother Res. 2022 Aug;36(8):3313-3324.|Redox Biol. 2021 Jan;38:101807.|Redox Biol. 2024 May 17:73:103200.|Res Sq. 2024 Sep 05.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2021 Nov.|Research Square Preprint. 2024 Jan 8.|Research Square Preprint. 2024 Nov 06.|Research Square Print. October 6th, 2022.|RSC Adv. 2022, 12, 28104-28112.|Sci Adv. 2024 Jul 5;10(27):eadl1197.|Sci Transl Med. 2021 Jan 20;13(577):eaba7401.|SLAS Discov. 2018 Aug;23(7):687-696. |Stem Cells Int. 2023 Jan 30.|Surgery. 2024 Jan 31:S0039-6060(23)00963-7.|Technol Cancer Res Treat. 2024 Jan-Dec:23:15330338241241935.|Theranostics. 2021 Mar 24;11(12):5650-5674.|Transl Lung Cancer Res. 2024 Oct 31;13(10):2698-2712.|Transl Oncol. 2020 Sep;13(9):100804.|Transl Oncol. 2023 Oct 26:39:101803.|Transl Res. 2022.|Universidad de Granada. 2023 Mar 27.|University of Brescia. 2023 Feb 2.|University of Western Australia. 2024 Jul 28.|View. 2023 Nov 15.|Acta Biomater. 2023 Apr 21;S1742-7061(23)00220-9.|Acta Pharm Sin B. 2023 Oct;13(10):4253-4272.|Adv Sci (Weinh). 2022 May;9(15):e2105894.|Biomed J. 2020 Aug;43(4):368-374.|Br J Pharmacol. 2021 Jun;178(12):2496-2515.|Cancer Lett. 2024 Feb 6:587:216696.|Cancer Res. 2023 Jun 16;CAN-22-3346.|Chem Biol Interact. 2023 Nov 22:110816.|Heliyon. June 2022, e09643.|Int J Cancer. 2024 Jul 15;155(2):324-338.|Int J Nanomedicine. 2023 Jul 19.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Pharmacol Exp Ther. 2018 Oct;367(1):20-27.|JCI Insight. 2022 Oct 13;e159419.|Molecules. 2023 Nov 12, 28(22), 7552.|Onco Targets Ther. 2019 Jun 12;12:4585-4593. |Oncol Lett. 2023 Sep 20.|Oncotarget. 2017 Oct 6;8(52):90185-90196. |PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. |SSRN. 2024 Mar 14.|Urol Oncol. 2021 Mar;39(3):194.e1-194.e7.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  95058-81-4